These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31595181)

  • 21. Therapeutic potential of Bcl-x
    Perri M; Yap JL; Fletcher S; Cione E; Kane MA
    Oncol Lett; 2018 May; 15(5):7231-7236. PubMed ID: 29849791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-operation of MCL-1 and BCL-X
    Galas-Filipowicz D; Chavda SJ; Gong JN; Huang DCS; Khwaja A; Yong K
    Front Oncol; 2024; 14():1394393. PubMed ID: 38651147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-apoptotic Bcl-XL but not Mcl-1 contributes to protection against virus-induced apoptosis.
    Ohmer M; Weber A; Sutter G; Ehrhardt K; Zimmermann A; Häcker G
    Cell Death Dis; 2016 Aug; 7(8):e2340. PubMed ID: 27537523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-Bclx
    Bonnefond ML; Florent R; Lenoir S; Lambert B; Abeilard E; Giffard F; Louis MH; Elie N; Briand M; Vivien D; Poulain L; Gauduchon P; N'Diaye M
    Oncotarget; 2018 Sep; 9(74):33896-33911. PubMed ID: 30338034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity.
    Anantram A; Kundaikar H; Degani M; Prabhu A
    J Biomol Struct Dyn; 2019 Aug; 37(12):3109-3121. PubMed ID: 30526410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
    Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
    Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1.
    Ow TJ; Fulcher CD; Thomas C; Broin PÓ; López A; Reyna DE; Smith RV; Sarta C; Prystowsky MB; Schlecht NF; Schiff BA; Rosenblatt G; Belbin TJ; Harris TM; Childs GC; Kawachi N; Guha C; Gavathiotis E
    Oncotarget; 2019 Jan; 10(4):494-510. PubMed ID: 30728900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.
    Vikström IB; Slomp A; Carrington EM; Moesbergen LM; Chang C; Kelly GL; Glaser SP; Jansen JH; Leusen JH; Strasser A; Huang DC; Lew AM; Peperzak V; Tarlinton DM
    Cell Death Dis; 2016 Aug; 7(8):e2345. PubMed ID: 27560714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
    Tagscherer KE; Fassl A; Sinkovic T; Combs SE; Roth W
    Apoptosis; 2012 Feb; 17(2):187-99. PubMed ID: 22002102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
    Montraveta A; Xargay-Torrent S; Rosich L; López-Guerra M; Roldán J; Rodríguez V; Lee-Vergés E; de Frías M; Campàs C; Campo E; Roué G; Colomer D
    Oncotarget; 2015 Aug; 6(25):21159-72. PubMed ID: 26110568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
    Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
    Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis.
    Di Cristofano FR; Fong MW; Huntington KE; Carneiro BA; Zhou L; El-Deiry WS
    Am J Cancer Res; 2023; 13(1):307-325. PubMed ID: 36777502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
    Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
    Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.
    Modugno M; Banfi P; Gasparri F; Borzilleri R; Carter P; Cornelius L; Gottardis M; Lee V; Mapelli C; Naglich JG; Tebben A; Vite G; Pastori W; Albanese C; Corti E; Ballinari D; Galvani A
    Exp Cell Res; 2015 Mar; 332(2):267-77. PubMed ID: 25486070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
    Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.